Icatibant Wockhardt Uk (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition and clinical guidelines. Typically, a single subcutaneous injection is administered at the onset of an angioedema attack, and the prescriber may repeat the dose if needed according to approved protocols.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

The primary alternative for hereditary angioedema is plasma‑derived or recombinant C1‑inhibitor concentrate. While C1‑inhibitor replaces the deficient protein, icatibant directly blocks the bradykinin B2 receptor. Icatibant offers rapid symptom relief via subcutaneous injection, whereas C1‑inhibitor is administered intravenously and may require longer preparation time.

Icatibant should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, then return to refrigeration as soon as possible.

Icatibant is given as a subcutaneous injection, usually into the abdomen or thigh. The injection is performed using a sterile pre‑filled syringe or vial, following aseptic technique. Patients or healthcare providers can administer the dose at the first sign of an angioedema attack, and the injection site should be rotated for subsequent doses.

Serious adverse reactions include anaphylaxis, severe angioedema, hypotension, and rare cases of thrombocytopenia. If any signs of a severe allergic reaction—such as difficulty breathing, swelling of the face or throat, or a sudden drop in blood pressure—occur, seek emergency medical care immediately.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Patients with a history of severe allergic reactions to bradykinin‑targeting therapies should avoid its use, and clinicians should assess risk before prescribing.